Bust #14: The Little Pill Song, Slowed Down

🎬 Bust #14 · The Commercial As You See It

A Little Pill, A Big Musical, And A Whole Park Dancing

The Jardiance commercial does not walk into your living room. It tap-dances in. The famous hook calls it “a little pill with a big story to tell” — a once-daily pill, taken at each day’s start — and suddenly a normal day, an office, a town square, or a movie night in the park turns into a full musical number. Everybody sings. Everybody dances. The pill is small, the story is big, and the choreography is enormous.

One recent version turned movie night itself into the stage: a singer, a crowd dancing on lawn blankets, a giant popcorn world, a film projector flashing, cameras flashing — and, in the regulator’s own description, even a dog wearing 3D glasses. It is joyful, it is catchy, and it is exactly the kind of commercial this blog was built for.

Because while the park is dancing, the important words are doing their usual two jobs: racing by in the fast voiceover, and sitting in small type on the screen. To be fair — we are always fair here — the information IS in the ad. But this time we do not have to take our word for what the dancing does to it. The U.S. Food and Drug Administration reviewed one of these TV ads and put its opinion in writing. So today, we slow the whole thing waaay down, using the FDA-approved DailyMed label and the FDA’s own letter as our pause button.

🔍 The Fine Print, Slowed Waaay Down

What The Chorus Is Actually Singing Over

Here is the fine print, translated into normal human English from the DailyMed label for Jardiance (empagliflozin tablets), revised January 2026:

• “A big story” is really four different labeled stories. The label lists Jardiance, a sodium-glucose co-transporter 2 (SGLT2) inhibitor, to: reduce the risk of cardiovascular death and hospitalization for heart failure in adults with heart failure; reduce the risk of sustained decline in eGFR, end-stage kidney disease, cardiovascular death, and hospitalization in adults with chronic kidney disease at risk of progression; reduce the risk of cardiovascular death in adults with type 2 diabetes and established cardiovascular disease; and, as an adjunct to diet and exercise, improve glycemic control in adults and in pediatric patients aged 10 years and older with type 2 diabetes. Four specific groups, four specific jobs — not one general “feel better” promise for everybody.
• “Reduce the risk” does not mean “prevent.” That phrase is the label’s own wording, and it matters. A risk can be lowered and the event can still happen. The song sells the lowering. The label never promises the event is gone.
• It is not recommended for type 1 diabetes. The label says so plainly, and gives the reason: it may increase the risk of diabetic ketoacidosis in those patients. It is also not recommended to improve glycemic control in people with type 2 diabetes whose eGFR is less than 30, and it is not recommended for treating chronic kidney disease in people with polycystic kidney disease or in certain patients who need, or recently had, intravenous immunosuppressive therapy or more than 45 mg of prednisone or equivalent for kidney disease — the label says it is not expected to be effective in those populations.
• “Once daily” has a dose and a clock attached. The recommended dosage is 10 mg orally once daily in the morning, taken with or without food. Only for additional glycemic control may the dosage be increased to 25 mg once daily, in patients tolerating it. And the label adds a rule no jingle mentions: withhold Jardiance for at least 3 days, if possible, before surgery or procedures associated with prolonged fasting, and resume it when the patient is clinically stable and eating again.
• The ketoacidosis warning hides a trap for the unwary. The label describes ketoacidosis as a serious, life-threatening condition requiring urgent hospitalization, reports that fatal cases have occurred, and warns that it may be present even if blood glucose levels are less than 250. In plain English: a “normal-looking” blood sugar number does not rule it out. The label lists its signs as nausea, vomiting, abdominal pain, generalized malaise, and shortness of breath, and tells patients to stop the medicine and seek medical attention immediately if signs and symptoms occur.
• It can lower the body’s fluid volume. The label warns that Jardiance can cause intravascular volume depletion, which may show up as symptomatic low blood pressure or acute changes in kidney tests, and it notes post-marketing reports of acute kidney injury, some requiring hospitalization and dialysis, in patients with type 2 diabetes receiving SGLT2 inhibitors including this one. People with impaired renal function, elderly patients, and patients on loop diuretics are named as being at increased risk, which is why the label says to assess volume status and renal function before starting.
• The infection list is longer than the dance number. The label says treatment increases urinary glucose excretion and increases the risk of genitourinary infections. Serious ones reported include urosepsis and pyelonephritis — serious urinary tract infections requiring hospitalization — and necrotizing fasciitis of the perineum, also called Fournier’s gangrene, described as a rare but serious and life-threatening infection requiring urgent surgical intervention, with serious outcomes that have included hospitalization, multiple surgeries, and death. The label’s highlights name the most common adverse reactions, at 5% or greater incidence, as urinary tract infections and female genital mycotic infections.
• Low blood sugar depends on what else is on board. In adults, the label says the risk of hypoglycemia may be increased when Jardiance is used together with insulin or an insulin secretagogue such as a sulfonylurea, and that lowering the dose of those other medicines may lower that risk. In pediatric patients aged 10 years and older, the risk was higher regardless of insulin use.
• There are also foot and allergy warnings. The label tells clinicians to monitor patients for infections or ulcers of the lower limbs and counsel patients about routine preventative foot care, and it lists serious hypersensitivity reactions, such as angioedema, as a reason to stop the medicine and treat promptly. Hypersensitivity to empagliflozin or any ingredient in the tablets is the label’s contraindication.

None of that means the medicine is “bad.” It means the “big story” is genuinely big — four labeled uses, a morning dose, kidney-function limits, a surgery pause, and a warning list that deserves more than a chorus line.

🧠 What The Song Doesn't Spell Out

The Night The Regulator Reviewed The Choreography

1. The FDA said the dancing itself was the problem in one specific ad. In an untitled letter dated September 9, 2025, the FDA said it had reviewed a direct-to-consumer TV ad for Jardiance — the “movie night” version — and determined that the TV ad is false or misleading, and that it therefore misbrands the drug. The letter’s reasoning is this blog in one paragraph: fast-paced visuals, choreographed dancing throughout multiple scene changes, enlarged popcorn bucket props, a ticket booth, a movie screen, lawn blankets, flashing cameras, a photo stand-in, a man throwing popcorn and catching it in his mouth, a film projector with flashing lights, and a dog wearing 3D glasses all compete for attention while the indications and limitations are presented. Fairness note: that finding is about that TV ad’s presentation. It is not a finding that the medicine does not work for its labeled uses — and the FDA asked the company to stop using promotional communications that are misleading in that way and to respond in writing within 15 working days.

2. The FDA also called out the tiny type directly. The same letter says the size and style of font, contrast with the background, and placement on screen of the text portion of the major statement do not allow the information to be read easily, and that the frequent scene changes and attention-grabbing visuals during the major statement interfere with comprehension of it. That is the exact trick this blog slows down every day — confirmed here, in writing, by the regulator, for this ad.

3. “Little pill” is a size, not a simplicity score. The tablet comes in just two strengths, 10 mg and 25 mg, and the morning routine sounds as simple as a song. The label around it is not simple: kidney function and volume status are assessed before starting, the dose only rises for one of the four jobs (glycemic control), the medicine is paused around surgery and prolonged fasting, and a “do not double up” rule covers a missed dose. Small pill, long instruction sheet.

4. The ad still never does the pharmacy-counter math. Commercials in this series sing about the pill, not about coverage, prior authorizations, or what a given person’s plan will actually require at the counter. The song delivers the feeling. The pharmacy delivers the math. Those remain two very different conversations — and only one of them is sung.

⚖️ The Busters Verdict

Verdict: The Truth Was On Screen — The FDA Said The Dance Buried It

This is the rare bust where we do not have to argue about whether the fine print was hard to follow. For the movie-night TV ad, the FDA said so itself: the presentation undermined the indications and limitations, created a misleading impression about efficacy, and made the major statement hard to read and hard to comprehend. The label underneath is serious and specific — risk reduction for defined groups of adults, glycemic control for a defined group aged 10 and older, no recommendation for type 1 diabetes, kidney-function limits, and warnings covering ketoacidosis, volume depletion, serious infections, low blood sugar with certain other medicines, lower-limb problems, and allergic reactions.

So here is your Commercial Busters homework — the questions worth taking to a doctor or pharmacist, because they are the professionals and we are not:

• “Which of the label’s four uses, if any, is the one being considered for me — heart failure, chronic kidney disease, cardiovascular risk with type 2 diabetes, or glycemic control?”
• “What do my kidney function (eGFR) and volume status mean for the label’s limits and warnings in my case?”
• “How would I recognize ketoacidosis if it can happen even when blood sugar is less than 250, and what exactly should I do if those signs appear?”
• “Do the other medicines I take — especially insulin, a sulfonylurea, or a loop diuretic — change any of these risks for me?”
• “What is the plan for pausing this medicine before surgery or a procedure with prolonged fasting, and for foot care and infection checks while I take it?”
• “What will this actually cost me every month, with my coverage?”

Sources you can check yourself: the DailyMed label for Jardiance (empagliflozin tablet, film coated), Boehringer Ingelheim Pharmaceuticals, Inc., revised January 2026 — indications and limitations of use, dosage (10 mg once daily in the morning; may increase to 25 mg for glycemic control; withhold at least 3 days before surgery or prolonged fasting), contraindication, and warnings for ketoacidosis, volume depletion, genitourinary infections including Fournier’s gangrene, hypoglycemia, lower limb amputation monitoring, and hypersensitivity (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?audience=consumer&setid=5777b8a8-ada6-4950-8548-43a1de11f075); and the U.S. Food and Drug Administration untitled letter to Boehringer Ingelheim Pharmaceuticals, Inc. dated September 9, 2025 (NDA 204629 / MA 4235), reviewing the “movie night” direct-to-consumer TV ad, determining it false or misleading, and describing the dancing, scene changes, popcorn props and 3D-glasses dog, and the font size, style, contrast, and placement of the major statement (https://www.fda.gov/media/188746/download?attachment=).

Final reminder: This post is for educational and entertainment purposes only. It is not medical, financial, legal, insurance, or any other professional advice, and it should not be used to make any kind of decision. Talk to a qualified professional about your own situation. Please do not contact us about the products, drugs, policies, or services covered here — we do not provide advice on any of them.